0
0
European health authorities have lifted previous restrictions on the use of Valneva’s chikungunya vaccine for adults aged 65 and older, marking a significant expansion in access to the world’s first approved vaccine against the mosquito-borne virus.
The decision, announced on Friday, follows a review of new clinical data demonstrating the vaccine’s safety and efficacy in older populations. The European Medicines Agency (EMA) had initially limited the vaccine’s use to adults aged 18 to 64 when it granted approval in 2023, citing insufficient evidence for the elderly demographic. The latest move means that adults over 65 across the European Union will now be eligible to receive the vaccine, which is administered as a single dose.
Chikungunya, transmitted by Aedes mosquitoes, can cause debilitating joint pain, fever, and rash. While rarely fatal, the disease can be particularly severe in older adults and those with underlying health conditions. The expansion of vaccine eligibility is expected to bolster protection for vulnerable groups, especially as climate change and global travel contribute to the spread of mosquito-borne diseases in new regions.
Valneva, a French specialty vaccine company, welcomed the decision, stating that it will work with European governments to ensure broad access for those most at risk. The company is also seeking similar label expansions in other major markets.
The EMA’s updated guidance comes amid growing concern over the increasing incidence of chikungunya outbreaks in southern Europe and other temperate regions.
Disclaimer: This article is based on information available as of July 12, 2025. It does not constitute medical advice. For personalized recommendations, consult a qualified healthcare professional.
